We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
PUT
NVIDIA
NVDA
$5.01T
| $15.9M | 0.04% |
1,087,000
-2,672,000
| -71% | -$39.2M |
|
552
Protagonist Therapeutics
PTGX
$8.75B
| $15.9M | 0.04% |
1,454,446
+639,720
| +79% | +$5.4M |
|
|
SJI
553
DELISTED
South Jersey Industries, Inc.
SJI
| $15.9M | 0.04% |
446,324
+413,110
| +1,244% | +$14.3M |
|
554
VanEck Emerging Markets High Yield Bond ETF
HYEM
$522M
| $15.8M | 0.04% |
868,799
+603,477
| +227% | +$10.5M |
|
555
CALL
Chevron
CVX
$388B
| $15.8M | 0.04% |
87,900
+25,700
| +41% | +$4.48M |
|
556
BRC Group Holdings
RILY
$277M
| $15.8M | 0.04% |
460,835
+455,335
| +8,279% | +$19.1M |
|
|
PNTM
557
DELISTED
Pontem Corporation
PNTM
| $15.7M | 0.04% |
1,557,628
-1,611,071
| -51% | -$16.2M |
|
558
monday.com
MNDY
$3.27B
| $15.7M | 0.04% |
128,821
+88,632
| +221% | +$9.22M |
|
559
Amgen
AMGN
$203B
| $15.6M | 0.04% |
59,351
-20,213
| -25% | -$5.42M |
|
560
Lyft
LYFT
$5.39B
| $15.6M | 0.04% |
+1,412,641
| New | +$17M |
|
561
Public Storage
PSA
$60.2B
| $15.5M | 0.04% |
+55,490
| New | +$16.2M |
|
562
Ultragenyx Pharmaceutical
RARE
$2.65B
| $15.5M | 0.04% |
335,425
+254,711
| +316% | +$10M |
|
|
KVSA
563
DELISTED
Khosla Ventures Acquisition Co. Class A Common Stock
KVSA
| $15.5M | 0.03% |
1,554,651
| – | – |
|
|
AONC
564
DELISTED
American Oncology Network, Inc. Class A Common Stock
AONC
| $15.5M | 0.03% |
1,545,109
| – | – |
|
565
Vaxcyte
PCVX
$7.89B
| $15.5M | 0.03% |
+322,600
| New | +$12.7M |
|
566
iShares MSCI Mexico ETF
EWW
$1.89B
| $15.4M | 0.03% |
311,246
+211,098
| +211% | +$10.6M |
|
567
Core & Main
CNM
$8.17B
| $15.3M | 0.03% |
793,544
+156,865
| +25% | +$3.34M |
|
|
SDAC
568
DELISTED
Sustainable Development Acquisition I Corp. Class A Common Stock
SDAC
| $15.3M | 0.03% |
1,522,189
| – | – |
|
569
iShares JPMorgan EM High Yield Bond ETF
EMHY
$618M
| $15.3M | 0.03% |
+437,544
| New | +$14.8M |
|
570
Fidelity National Information Services
FIS
$21.5B
| $15.3M | 0.03% |
225,247
+135,078
| +150% | +$9.6M |
|
571
GoodRx Holdings
GDRX
$1B
| $15.2M | 0.03% |
3,272,408
-350,301
| -10% | -$1.73M |
|
572
CALL
Visa
V
$677B
| $15.2M | 0.03% |
73,300
-24,900
| -25% | -$5.02M |
|
|
TRTL
573
DELISTED
TortoiseEcofin Acquisition Corp. III
TRTL
| $15.2M | 0.03% |
1,522,643
| – | – |
|
574
CALL
Salesforce
CRM
$134B
| $15.1M | 0.03% |
114,100
-22,600
| -17% | -$3.3M |
|
|
FLG
575
Flagstar Bank National Association
FLG
$5.77B
| $15.1M | 0.03% |
+585,989
| New | +$15.7M |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.